The comparative risk for gastrointestinal bleeding (GIB) with non-vitamin K antagonist oral anticoagulants (NOACs) was compared to vitamin K antagonists or anti-platelet agents in a recent metanalysis, which showed no significant difference in major GIB events between these agents.
It’s a great time to be a rheumatologist and to manage RA. But, if you keep doing what you’re doing, you’re going to keep getting what you’ve got.
Dr. John Cush RheumNow
7 years 2 months ago
18 mos study of 78 patients with ANCA Assoc Vasculitis showed baseline IL-6 levels correlate with PR3-ANCA (not MPO) titers; while assoc w/ certain Sxs (fever, pulm nodules/cavities), deafness, RBC casts; sIL6 levels did not predict responses at 6 mos https://t.co/jawVLOSQnZ
Dr. John Cush RheumNow
7 years 2 months ago
Dannish MRI study of 204 people (including 41 #AxSpA) shows that sacroiliac bone marrow edema is nonspecific, seen in 3-39% of non-SpA. Only SI erosions erosions, backfill & ankylosis were specific for axSpA. Few women w/ postpartum pain had SI erosion https://t.co/7iMaKGEafJ
Lancet has reported on a clinical trial comparing total knee replacement (TKR) and partial knee replacement (PKR) in late-stage isolated medial compartment knee osteoarthritis patients finding that both TKR and PKR are equally effective, PKR should be considered the first, because of lower costs and better cost-effectiveness.
Dr. John Cush RheumNow
7 years 2 months ago
Weight loss does not reduce #RA risk. Swedish Obese (SOS) study followed 2002 bariatric surgery pts & 2034 controls. Overall 92 developed RA; RA risk now lower w/ bariatric surgery (HR 0.92; CI 0.59, 1.46) nor did wt loss; but CRP & smoking were https://t.co/bFKiPWvKRQ
Dr. John Cush RheumNow
7 years 2 months ago
Study from National Inpatient Sample (2002-11) , 424 hospitals, 4024 #SLE pts admitted w/ sepsis. Mortality varied from 0-60%. Hospitals that treated ⩾3.9 patients with SLE and sepsis annually had a lower risk of lupus mortality (10% vs 17%; P = 0.004). https://t.co/TuVfaGUpcM
Dr. John Cush RheumNow
7 years 2 months ago
Mayo Clinic study shows that once #RA is diagnosed with CHF, hospitalization rates were significantly higher in RA vs non-RA (RR 1.17; CI 1.08-1.26). RA \more likely to be hospitalized for non-cardiovascular (RR 1.26); not for CHF or other CV causes. https://t.co/r5fvygpAE9
The US Food and Drug Administration (FDA) has approved apremilast (Otezla) for the treatment of oral ulcers associated with Behçet’s Disease, a rare chronic multisystem inflammatory disease that affects about 5 in 100,000 persons in the USA.
Dr. John Cush RheumNow
7 years 2 months ago
40 years since the "House of God" by Samuel Shem, Dr. Len Calabrese's recollects on the books 40th anniversary. Join his summer book club and add some commentary! https://t.co/L8wiGpWk42
Dr. John Cush RheumNow
7 years 2 months ago
Nearly half of Americans believe that the U.S. health care and health care providers are not compassionate. Studies show less than half of physicians and clergy exhibit compassion. (from COMPASSIONOMICS by Trseciak & Mazzarelli) https://t.co/z0F7Ql5oR3
Dr. John Cush RheumNow
7 years 2 months ago
The RheumNow Podcast is up! Discussions on MDA-5 Abs & DM; gout & narcotics; IA capsaicin in OA; and ADA vs UPA. Watch here>> https://t.co/gZRJ2eHCqB or listen on iTunes or SoundCloud>> https://t.co/x6mCEqg6gU
Dr. John Cush RheumNow
7 years 2 months ago
FDA has approved Otezla 30 mg bid for adults with oral ulcers associated with Behcet's Disease; based on the results showing apremilast lowers the number and pain of oral ulcers in a 12-week placebo-controlled Phase 3 study https://t.co/QeIXxsHxtY
Dr. John Cush RheumNow
7 years 3 months ago
FDA has approved Otezla 30 mg bid for adults with oral ulcers associated with Behcet's Disease; based on the results showing apremilast lowers the number and pain of oral ulcers in a 12-week placebo-controlled Phase 3 study. https://t.co/QeIXxsHxtY
